Related Experiment Video
Updated: Jan 11, 2026
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
Emerging advances in CAR-T therapy for solid tumors: latest clinical trial updates from 2025 ASCO annual meeting
Wenze Li1, Defeng Zhao2, Miao Chen3
1Department of Hematology, The First Hospital of China Medical University, 155N. Nanjing Street, Shenyang, 110001, Liaoning, China.
Abstract:
Chimeric antigen receptor T-cell (CAR-T) therapy has demonstrated a transformative impact in hematologic malignancies and offers a promising strategy to offer new hope for patients with solid tumors who have failed multiple lines of treatment. The clinical application of CAR-T therapy in solid tumors, however, still has challenges, including tumor heterogeneity, an immunosuppressive tumor microenvironment, and safety concerns. These hurdles have mean that CAR-T therapy has become both a focal point and a pivotal trend in contemporary clinical research. The American Society of Clinical Oncology (ASCO) Annual Meeting serves as a premier venue for unveiling groundbreaking clinical data. In this review, we highlight the main phase I clinical trial advances in CAR-T therapy for solid tumors presented at the 2025 ASCO Meeting.
Insights
Chimeric antigen receptor T-cell (CAR-T) therapy shows promise for solid tumors, but faces challenges like tumor heterogeneity and immunosuppression. This review highlights recent phase I trial advances presented at the 2025 ASCO Meeting.
Area of Science:
- Oncology
- Immunotherapy
Background:
- Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized hematologic malignancy treatment.
- CAR-T therapy offers potential for solid tumors in patients with refractory disease.
- Significant challenges impede CAR-T therapy efficacy in solid tumors, including tumor heterogeneity and the immunosuppressive tumor microenvironment.
Conclusions:
- CAR-T therapy remains a pivotal research trend for solid tumors.
- Ongoing clinical trials presented at ASCO 2025 indicate progress in the field.
More Related Videos
Related Concept Videos
02:56Treatment Resistant Cancers
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...